Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma | Future Oncology
3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview | eviQ
Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study | BMJ Open
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
Multiple Myeloma in: Journal of the National Comprehensive Cancer Network Volume 9 Issue 10 (2011)
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts
VAD and similar alternate regimens | Download Table
3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview | eviQ
Multiple myeloma current treatment algorithms | Blood Cancer Journal
Additional Trials | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
NCCN guidelines version l. 2013 multiple myeloma | Download Table
Multiple myeloma current treatment algorithms | Blood Cancer Journal
BORTDEXADARA Regimen
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study - Yimer - 2019 - British Journal of Haematology - Wiley Online Library
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. - Abstract - Europe PMC
Hematology treatment policies: Plasma cell neoplasms - Sunnybrook Hospital
